Recurv Pharma

About:

Recurv Pharma is developing a brand-new taxane therapy for the treatment of solid tumours.

Top Investors: TVM Capital Life Science

Description:

Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers, has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.